Physician profile
Rodney Smith
NPI 1144290917
$2,693.84
in general payments reported to CMS, 2019-2025
29 companies · $117 in 2025
The $117 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $191 · 2021: $593 · 2022: $450 · 2023: $463 · 2024: $450 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $956 · Education: $73.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $955.83 |
| Education | $73.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $867.01 | 2020-2024 | Vraylar, Ubrelvy, Qulipta |
| Astellas Pharma US INC | $431.50 | 2019-2024 | Veozah |
| Glaxosmithkline, LLC. | $295.09 | 2021-2024 | Bexsero, Shingrix, Arexvy |
| Novo Nordisk INC | $145.45 | 2019-2023 | Ozempic, Rybelsus |
| Allergan, INC. | $142.78 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $123.47 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $103.95 | 2021-2024 | Rexulti |
| Inspire Medical Systems, INC. | $63.97 | 2025 | Inspire |
| Scilex Pharmaceuticals INC. | $56.72 | 2019 | |
| Eisai INC. | $54.94 | 2020-2021 | |
| Kaleo, INC. | $52.66 | 2019 | |
| Amarin Pharma, INC. | $47.12 | 2021 | |
| Pfizer INC. | $43.45 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $41.44 | 2019 | |
| Esperion Therapeutics, INC. | $31.83 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $18.62 | 2021 | |
| Jazz Pharmaceuticals INC. | $17.62 | 2022 | |
| Boston Scientific Corporation | $16.94 | 2025 | General - Pain Management |
| Biodelivery Sciences International, INC. | $16.05 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.61 | 2021 | |
| Lilly USA, LLC | $14.11 | 2022 | |
| Exact Sciences Corporation | $13.63 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $13.21 | 2020 | |
| Genentech USA, INC. | $12.91 | 2019 | |
| Amgen INC. | $12.33 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.92 | 2019 | |
| Ibsa Pharma INC. | $11.91 | 2022 | |
| Daiichi Sankyo INC. | $11.87 | 2020 | |
| Phathom Pharmaceuticals, INC. | $6.73 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.